36 Series B medtech investors in the US
We list 36 Series B medtech investors in the US as of November 2026: each has an SEC filing on file, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are Boston (3), Nashville (2) and New York (2).
Top 5 Series B medtech investors in the US, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Arboretum Ventures
Type: VC firm · HQ: Ann Arbor, MI · Stages: Series A, Series B · Focus: Medtech, Healthtech, Biotech · Latest activity: Portfolio news, Mar 2026 · Fund size on file: $250M (SEC Form D, 2022)
Portfolio news dated Mar 2026; $250M fund on file (SEC Form D, 2022); 39% of its observed portfolio is medtech and medical devices; backs Series A, Series B; names the US as where it invests; 7 named decision-makers on file.
How Women Invest
Type: VC firm · HQ: Oakland, CA · Stages: Pre-seed, Seed, Series A, Series B · Focus: Medtech, Healthtech, AI, B2B · Latest activity: New fund, Sep 2026 · Fund size on file: $12M (SEC Form D, 2026)
Latest fund filing dated Sep 2026; $12M fund on file (SEC Form D, 2026); 21% of its observed portfolio is medtech and medical devices; backs pre-seed, seed, Series A; names the US as where it invests; 8 named decision-makers on file.
Claritas Signal Partners
Type: VC firm · HQ: Nashville, TN · Stages: Seed, Series A, Series B, Growth · Focus: Medtech, Healthtech, AI, Media · Latest activity: New deal, Aug 2026 · Fund size on file: $14M (SEC Form D, 2021)
Dated new deal in Aug 2026; $14M fund on file (SEC Form D, 2021); 70% of its observed portfolio is medtech and medical devices; backs seed, Series A, Series B; 8 named decision-makers on file.
Ansa
Type: VC firm · HQ: New York, NY · Stages: Series A, Series B, Growth · Focus: Medtech, AI, Cybersecurity, Healthtech · Latest activity: New fund, May 2026 · Fund size on file: $200M (SEC Form D, 2026)
Latest fund filing dated May 2026; $200M fund on file (SEC Form D, 2026); 15% of its observed portfolio is medtech and medical devices; backs Series A, Series B, growth-stage; names the US as where it invests; 4 named decision-makers on file.
S3 Ventures
Type: VC firm · HQ: Austin, TX · Stages: Seed, Series A, Series B · Focus: Medtech, Healthtech, Developer Tools, SaaS · Latest activity: New fund, Sep 2025 · Fund size on file: $150M (SEC Form D, 2022)
Latest fund filing dated Sep 2025; $150M fund on file (SEC Form D, 2022); 50% of its observed portfolio is medtech and medical devices; backs seed, Series A, Series B; names the US as where it invests; 1 named decision-maker on file.
First 18 of 36 Series B medtech investors in the US
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Arboretum Ventures | VC firm | Ann Arbor, MI | Series A, Series B | Medtech, Healthtech, Biotech | Portfolio news, Mar 2026 | $250M (SEC Form D, 2022) | 5 Nov 2026 | 7 names · Unlock |
| How Women Invest | VC firm | Oakland, CA | Pre-seed, Seed, Series A, Series B | Medtech, Healthtech, AI, B2B | New fund, Sep 2026 | $12M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
| Claritas Signal Partners | VC firm | Nashville, TN | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Media | New deal, Aug 2026 | $14M (SEC Form D, 2021) | 5 Nov 2026 | 8 names · Unlock |
| Ansa | VC firm | New York, NY | Series A, Series B, Growth | Medtech, AI, Cybersecurity, Healthtech | New fund, May 2026 | $200M (SEC Form D, 2026) | 4 Nov 2026 | 4 names, firm email · Unlock |
| S3 Ventures | VC firm | Austin, TX | Seed, Series A, Series B | Medtech, Healthtech, Developer Tools, SaaS | New fund, Sep 2025 | $150M (SEC Form D, 2022) | 4 Nov 2026 | 1 name · Unlock |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Robotics | New deal, Sep 2026 | 4 Nov 2026 | 3 names, firm email · Unlock | |
| FCA Venture Management Group | VC firm | Nashville, TN | Seed, Series A, Series B | Medtech, Healthtech, AI, Biotech | Portfolio news, May 2026 | $58M (SEC Form ADV) | 5 Nov 2026 | 8 names · Unlock |
| Sandbox Clinical Ventures | VC firm | Chicago, IL | Seed, Series A, Series B, Growth | Medtech, Insurtech, Healthtech, AI | New fund, Sep 2026 | $100M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Cultivation Capital | VC firm | St. Louis, MO | Seed, Series A, Series B | Medtech, Healthtech, Biotech, SaaS | New fund, Sep 2026 | $100M (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| IVP: Venture capital for the Exceptional | VC firm | Menlo Park, CA | Series B, Growth | Medtech, AI, Healthtech, Developer Tools | New fund, Oct 2026 | $60M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Medtech, Healthtech, AI, Biotech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 4 Nov 2026 | 1 name · Unlock |
| Define Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Medtech, Healthtech, AI, Future of Work | New deal, Apr 2026 | $425M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| PACE Healthcare Capital | VC firm | Chicago, IL | Seed, Series A, Series B | Medtech, Healthtech | New deal, Apr 2024 | $75M (SEC Form D, 2024) | 5 Nov 2026 | 4 names, firm email · Unlock |
| Calculus VC | VC firm | Foster City, CA | Series A, Series B | Medtech, AI, Deep Tech, Healthtech | New deal, Aug 2026 | $1M (SEC Form D, 2025) | 4 Nov 2026 | 1 name, firm email · Unlock |
| SpringRock | VC firm | Seattle, WA | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, SaaS | New fund, Mar 2024 | $85M (SEC Form D, 2024) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Tau Ventures | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, B2B | New fund, Jul 2026 | 4 Nov 2026 | 8 names · Unlock | |
| Biomatics Capital | VC firm | Seattle, WA | Series B | Medtech, Healthtech, Biotech, Fintech | $141M (SEC Form ADV) | 5 Nov 2026 | firm email · Unlock | |
| BIP Ventures | VC firm | Atlanta, GA | Seed, Series A, Series B | Medtech, Healthtech, Fintech, Developer Tools | New fund, Aug 2026 | $20M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
You are seeing 18 of 36. The full list adds 18 more investors and 192 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 36 break down
By US state
| US state | On this list | Share |
|---|---|---|
| California | 9 | 25% |
| Massachusetts | 5 | 14% |
| Tennessee | 3 | 8% |
| Michigan | 2 | 6% |
| New York | 2 | 6% |
| Texas | 2 | 6% |
| Illinois | 2 | 6% |
| New Jersey | 2 | 6% |
| Washington | 2 | 6% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 35 | 97% |
| Corporate VC | 1 | 3% |
Method and limits
- Source
- All 36 rows carry an SEC filing (Form D or Form ADV). All 36 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states medtech and medical devices as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series B.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 6 Nov 2026.
- Fill rates
- Of 36 rows: stage 36, sector 36, fund size 29, website 36. In the paid file: named decision-makers on 34 rows, firm email on 15, LinkedIn page on 23, check size on 4.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many Series B medtech investors in the US are there?
We list 36 as of November 2026. 18 of the 36 have a fund filing or a dated deal in the last 12 months. The cities with the most are Boston (3), Nashville (2) and New York (2).
Which Series B medtech investors in the US raised a new fund in the last 12 months?
11 of the 36 have a fund filing dated in the last 12 months. The most recent on this list are IVP: Venture capital for the Exceptional (Oct 2026), Cultivation Capital (Sep 2026) and How Women Invest (Sep 2026).
What is the typical fund size of Series B medtech investors in the US?
The median fund size on file for this list is $85M, across the 23 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 13 do not disclose a size there.
How do I contact Series B medtech investors in the US?
The paid file holds 192 named decision-makers across 34 of these 36 and a firm email for 15. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on Series B medtech investors in the US come from?
All 36 rows have an SEC filing on file (Form D or Form ADV). Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Medtech venture capital firms in the US (350)Series B investors in the US (165)Series B medtech investors (57)
Related lists
Seed medtech investors in the US (205)Series B AI investors in the US (126)Series B SaaS investors in the US (108)Pre-seed medtech investors in the US (95)Series A medtech investors in the US (76)Growth-stage medtech investors in the US (69)Series B healthtech investors in the US (69)Series B fintech investors in the US (59)Series B deep tech investors in the US (41)Series B cybersecurity investors in the US (37)Series B biotech investors in the US (34)Series B energy investors in the US (29)Series B industrial tech investors in the US (29)Series B consumer investors in the US (29)Series B hardware investors in the US (28)Series B B2B investors in the US (27)Series B climate tech investors in the US (27)Series B developer tools investors in the US (21)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to medtech and medical devices, Series B and the US. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.